V ascular endothelial growth factor (VEGF) signaling is essential for angiogenesis during development and postnatal organ growth, as well as in pathological conditions such as tumor. [1] [2] [3] [4] [5] [6] [7] VEGF binds to its receptor, VEGFR2 (Flk-1; hereafter referred to as Flk), on endothelial cells (ECs), inducing VEGFR2 homodimerization and autophosphorylation at several tyrosine residues to initiate signaling cascades required for EC proliferation and migration. [8] [9] [10] The amount of VEGFR2 on the cell surface controls the magnitude of signal transmission. 11 Its abundance is negatively regulated by internalization and degradation. [12] [13] [14] [15] These tightly regulated processes are vital for the development and maintenance of a normal vascular system. Prolonged VEGF signaling causes vascular leakage and inflammatory responses. 14 Epsins are a family of endocytic adaptor proteins required for internalization and degradation of ubiquitinated receptors. [16] [17] [18] [19] [20] Mammals express 3 distinct epsin genes (Epn1, Epn2, and Epn3). 21 Although epsin 3 expression is localized primarily to the stomach and epidermis, epsins 1 and 2 are widely expressed and have redundant functions. 17, 18, [21] [22] [23] Specifically, global deletion of epsins 1 and 2 results in embryonic lethality, largely attributable to epsins role in promoting Notch signaling in all cell types. 21 In addition to the endocytic adaptor function, the multivalent properties of epsins facilitate additional functions such as the regulation of GTPases involved in actin remodeling. 24, 25 However, the specific role epsins play in different cell types, or their implications in normal physiology and disease, remains elusive.
Objective-We previously showed that endothelial epsin deficiency caused elevated vascular endothelial growth factor receptor 2 (VEGFR2) and enhanced VEGF signaling, resulting in aberrant tumor angiogenesis and reduced tumor growth in adult mice. However, direct evidence demonstrating that endothelial epsins regulate angiogenesis specifically through VEGFR2 downregulation is still lacking. In addition, whether the lack of epsins causes abnormal angiogenesis during embryonic development remains unclear. Approach and Results-A novel strain of endothelial epsin-deleted mice that are heterozygous for VEGFR2 ( ) mice demonstrated that VEGFR2 reduction in epsin-depleted cells was sufficient to restore normal VEGF signaling, EC proliferation, EC migration, and EC network formation. These findings were complemented by in vivo wound healing, inflammatory angiogenesis, and tumor angiogenesis assays in which reduction of VEGFR2 was sufficient to rescue abnormal angiogenesis in endothelial epsin-deleted mice. Endothelial-specific deletion of epsins 1 and 2 specifically increases VEGF signaling, but not signaling of other angiogenic factors including fibroblast growth factor, platelet derived growth factor, epidermal growth factor, and transforming growth factor-β. 26 Furthermore, mice lacking endothelial epsins 1 and 2 exhibited excessive tumor angiogenesis with highly disorganized vessels and significantly increased vascular permeability. Epsin interacts with VEGFR2 through its ubiquitin-interacting motifs, leading to the VEGF-dependent downregulation of VEGFR2, thus acting as a negative regulator of VEGF signaling. 12, 26, 27 However, the role of epsins in regulating tumor angiogenesis, in which surrounding tumor cells secrete exaggerated amounts of VEGF, may not represent the role of epsins during embryonic/developmental angiogenic conditions. 3 Furthermore, although our previous data established a correlation between epsin loss and augmented VEGF signaling, presumably attributable to increased VEGFR2 levels in the absence of epsin-mediated internalization and degradation, direct evidence that epsin loss causes augmented VEGFR2 levels is missing. In other words, it remains to be determined whether epsins directly and specifically downregulate VEGFR2 to control developmental and pathological angiogenesis in vivo.
Conclusions-Our
Here, we report that endothelial epsin deletion during development caused defective embryonic angiogenesis and lethality. Using a novel strain of endothelial epsin-deleted mice that are also heterozygous for VEGFR2, we found that reduced VEGFR2 expression in vivo significantly improved the defective wound healing and pathological angiogenesis produced by the loss of endothelial epsins. Furthermore, reducing VEGFR2 expression in primary mouse ECs (MECs) suppressed heightened VEGF signaling and angiogenic responses including EC proliferation and migration. Our findings provide the first direct evidence that endothelial epsins function to control angiogenesis by specifically downregulating VEGFR2 to modulate the VEGF signaling fundamental for developmental or pathological angiogenesis.
Materials and Methods
Materials and methods are available in the online-only Supplement.
Results

Endothelial Epsins Are Essential for Embryonic Angiogenesis
To determine the role of endothelial epsins in regulating angiogenesis, we first engineered mice constitutively lacking endothelial epsins 1 Figure 1A ), suggesting that loss of endothelial epsins is a cause of the defective angiogenesis resulting in embryonic lethality. 21 Immunostaining with CD31, a vascular endothelial marker, revealed major vascular developmental defects, including increased vascular density and disorganized vascular networks, in E10 EC-DKO embryos ( Figure 1B) . 29 Further immunofluorescent staining analyses of cross sections from isolated embryonic midbrain, hindbrain, skin, and intestine revealed much denser and highly disorganized vascular networks in the EC-DKO embryonic tissues compared with WT (Figure 1C-1J ; Figure II in the online-only Data Supplement). In addition, detailed analysis of hindbrain cross sections revealed that loss of endothelial epsins promoted formation of a more elaborate subventricular vascular plexus ( Figure 1G ). Collectively, our findings demonstrated that endothelial epsins are critical for the regulation of embryonic angiogenesis.
Epsins Negatively Regulate VEGFInduced Angiogenic Responses in ECs
To determine whether epsins regulate embryonic angiogenesis through modulating EC proliferation, migration, or network formation, we used in vitro angiogenesis assays using isolated primary MECs. 26, 30 We measured EC proliferation by culturing WT or DKO MECs with or without VEGF stimulation in the presence of 5-ethynl-2′-deoxyuridine (EdU), which labels cells actively undergoing S-phase DNA replication. 31 The small VEGF-dependent increase in WT MEC EdU incorporation ( Figure 2A ) is consistent with previously established roles for VEGF signaling in EC proliferation. 6, 8, 9, 26, 32, 33 Depletion of epsins exaggerated VEGF-dependent proliferation in the DKO MECs ( Figure 2A ). We next used an in vitro scratch assay and matrigel tube formation assay to measure EC migration and network formation, respectively. 30 In the scratch assay, confluent WT or DKO MEC monolayers were evenly scarred and then stimulated with VEGF to induce migration. MEC migration was determined by measuring scratch width reduction. Unlike the proliferation assay, VEGF stimulation did not affect WT MEC migration but did significantly increase DKO MEC migration ( Figure 2B and 2C) . Similarly, the in vitro tube formation assay revealed a more robust VEGF-dependent endothelial tube network in DKO MECs ( Figure 2D and 2E). In summary, our in vitro functional assays support an antiangiogenic function for epsins in the regulation of angiogenesis through limiting VEGFdependent EC proliferation, migration, and tube formation.
We also examined whether VEGF can stimulate the phosphorylation of accumulated cell surface VEGFR2 in DKO MECs. Five minutes of VEGF stimulation was sufficient to induce phosphorylation of VEGFR2 in both WT and DKO MECs with heightened VEGFR2 phosphorylation in DKO MECs ( Figure 2F ). Prolonged stimulation of WT MECs resulted in the loss of both phosphorylated and cell surface VEGFR2, indicating receptor degradation. In contrast, phosphorylated and cell surface VEGFR2 remained elevated in the DKO MECs . In contrast, a significant portion of the phosphorylated VEGFR2 in DKO MECs remained localized at the plasma membrane and failed to colocalize with EEA1 ( Figure  III in the online-only Data Supplement). In summary, our biochemical and cell biology approaches revealed that endothelial epsin depletion significantly impaired VEGFR2 internalization and degradation, resulting in prolonged VEGFR2 phosphorylation. It is important, however, to note that the cell surface level of a housekeeping protein, transferrin receptor, did not change in response to epsin depletion, indicating the specificity of epsins for regulating VEGFR2 ( Figure 2F ).
Genetic Reduction of VEGFR2 Expression Suppresses Upregulated In Vitro Angiogenesis Caused by Epsin Deficiency
To directly test whether the defective angiogenesis caused by endothelial epsin deletion is a result of heightened VEGFR2 and enhanced VEGF signaling, we crossed . 34 The iCDH5 Cre deleter mice specifically express Cre in ECs after tamoxifen treatment, resulting in a VEGFR2 heterozygote on an inducible EC-specific epsins 1 and 2 deleted background (EC-iDKO-Flk fl/+ ). 35, 36 Loss of a single Flk allele was sufficiently reduced VEGFR2 expression by ≈50% in the liver, lungs, and heart extracted from EC-iDKO-Flk fl/+ mice ( Figure 3A ). It is important to note that postnatal deletion of epsins did not affect quiescent postnatal angiogenesis. 26 with WT (data not shown). We also isolated and treated MECs with tamoxifen ex vivo, resulting in sufficient epsin 1 deletion and an ≈50% reduction of the VEGFR2 in DKO-Flk fl/+ MECs ( Figure 3B ). We measured EC proliferation via both in vitro EdU incorporation and in vivo 5-bromo-2-deoxyuridine incorporation. In the in vitro study, WT, DKO, or DKO-Flk fl/+ MECs were treated with VEGF in the presence of EdU as described above. Immunofluorescent detection revealed reduced EdU incorporation in the DKO-Flk fl/+ MECs to levels comparable with WT ( Figure 3C and 3D) . To confirm these findings in vivo, we injected 5-bromo-2-deoxyuridine into WT, EC-iDKO, and EC-iDKO-Flk fl/+ P6 pups and then isolated the intestine, a tissue that continuously undergoes postnatal angiogenesis. Consistently, reduced VEGFR2 expression in the EC-iDKOFlk fl/+ pups reduced the 5-bromo-2-deoxyuridine incorporation within the intestinal vasculature ( Figure 3E and Figure IV in the online-only Data Supplement). The findings strongly suggest that reduced VEGFR2 sufficiently rescues the enhanced proliferative phenotype resulting from loss of epsins.
Next, we determined whether reducing VEGFR2 also recovers normal levels of VEGFR2 phosphorylation, signaling, and cell migration in DKO MECs. First, using immunoblotting, we determined that reducing the VEGFR2 expression in DKO-Flk fl/+ MECs significantly reduced the VEGF-dependent phosphorylation of VEGFR2, as well as the downstream activation of phospholipase C gamma (PLCγ), Akt/protein kinase B, and extracellular signal-regulated kinase (ERK) ( Figure 4A and Figure V in the online-only Data Supplement). More importantly, these reductions corresponded to levels similar to WT MECs. Next, we compared the migration of DKO-Flk fl/+ MECs with WT and DKO MECs using the scratch assay. Reduced VEGFR2 levels significantly hindered DKO MEC migration such that the wound distance in the DKO-Flk fl/+ MECs was significantly larger than DKO MECs, but comparable with WT MECs (Figure 4B and 4C) . In summary, our findings strongly support our hypothesis that the proangiogenic phenotype of the epsin-deleted ECs was caused specifically by impaired downregulation of VEGFR2 activation.
Genetic Reduction of VEGFR2 Levels Restores Normal In Vivo Angiogenesis During Wound Healing
To test whether genetic reduction of VEGFR2 is sufficient to rescue abnormal angiogenesis in epsin deficiency in vivo, we used a wound healing assay that measures angiogenesis after postnatal dorsal wounds are generated by biopsy punches. 26 We found that EC-iDKO mice exhibited disorganized wound vasculature and a significantly delayed wound healing, suggesting defective angiogenesis ( Figure 5A-5C) . Importantly, the EC-iDKO-Flk fl/+ mice exhibited a wound healing curve and wound vasculature comparable with that of WT mice ( Figure 5B and 5C ). In addition, we used a streptozotocin (STZ)-induced diabetic mouse model, in which angiogenesis is greatly compromised, to investigate the effects of epsin deficiency and modulating VEGFR2 expression in wound healing. Compared with STZ-WT mice, STZ-EC-iDKO mice exhibited more rapid wound healing ( Figure 5D ), suggesting that boosting angiogenesis by depleting epsins plays a beneficial role in promoting diabetic wound healing. These results demonstrated the importance of epsins for balanced VEGFR2 protein levels during angiogenesis and suggested that epsins are a potential novel therapeutic target in treating diabetic ulcer.
Genetic Reduction of VEGFR2 Levels Rescues Defective Angiogenesis Under Pathological Conditions In Vivo
To determine whether VEGFR2 reduction rescues abnormal pathological angiogenesis in the absence of epsins, we first subcutaneously implanted VEGF-containing matrigel plugs in WT, EC-iDKO, or EC-iDKO-Flk fl/+ mice. 37 ) analyzed by immunoblot using the specified antibodies. B, Mouse endothelial cells (MECs) isolated from WT, EC-iDKO, or EC-iDKO-Flk fl/+ mice were treated ex vivo with 4-hydroxytamoxifen for 2 days, and then whole cell lysates were analyzed by immunoblot using the specified antibodies. C, MEC monolayers isolated from WT, EC-iDKO, or EC-iDKO-Flk fl/+ mice were labeled with 5-ethynl-2′-deoxyuridine (EdU) for 16 hours in the presence of 50 ng/mL VEGF-A and then fixed and immunostained for CD31 and EdU. D, Quantification of in vitro EdU incorporation in C. Error bars indicate mean±SEM. n>5; *P<0.05. E, Intestines isolated from 5-bromo-2-deoxyuridine (BrdU) injected WT, EC-iDKO, or EC-iDKO-Flk fl/+ mice were processed for in vivo CD31 and BrdU immunostaining. Scale bars: C and E, 50 μm.
immunofluorescent staining of the matrigel plugs, was dramatically increased in the EC-iDKO mice, compared with WT ( Figure 5E and 5F). Reduced VEGFR2 expression normalized the excessive angiogenic phenotype in EC-iDKO-Flk fl/+ mice to levels comparable with WT ( Figure 5F ). Aberrant angiogenesis in the EC-iDKO matrigel plugs was reminiscent of our previously established phenotype in which endothelial epsin deletion significantly enhanced the formation of dysfunctional, leaky vasculature in tumors. 26 However, it was unknown whether reducing VEGFR2 expression in the tumor is sufficient to rescue this epsin-deleted phenotype. To test this, we used a Lewis lung carcinoma xenograft model in the WT, EC-iDKO, and EC-iDKO-Flk fl/+ mice. Consistent with our previous findings, epsin deletion significantly reduced tumor growth ( Figure 5G and 5H) as a result of the enhanced formation of nonproductive vasculature within the tumor ( Figure 5I and 5J). Interestingly, reduced VEGFR2 expression promoted tumor growth in the EC-iDKO-Flk fl/+ mice to sizes comparable with WT ( Figure 5G and 5H) . Furthermore, the increased tumor growth correlated with normalized vasculature in the tumor ( Figure 5I and 5J) . Cumulatively, these findings support our model that endothelial epsin deletion resulted in aberrant embryonic and pathological angiogenesis by prolonging activation of VEGFR2. These results indicated that endothelial epsins specifically downregulate VEGFR2 as a negative feedback regulator for VEGFR2 activation and angiogenesis.
Discussion
In this study, we demonstrate a role for endothelial epsins as negative regulators to limit unwanted embryonic angiogenesis. Most importantly, by crossing endothelial epsin-deleted mice with mice heterozygous for VEGFR2, we provided the first direct evidence that endothelial epsin deficiency promotes angiogenesis by specifically increasing the total amount of cell surface VEGFR2 during angiogenesis ( Figure 6A ).
We used complementary constitutive and inducible endothelial epsin deletion models to address the specific and temporal role of endothelial epsins. First, using the constitutive Tie2 Cre deleter mice allowed us to identify, for the first time, an important role for endothelial epsins in embryonic angiogenesis. Importantly, the Tie2 Cre deleter mice exhibited delayed lethality and reduced phenotype severity than global epsins 1 and 2 deletion, consistent with the hypothesis that EC-specific epsin deletion specifically altered VEGFR2 signaling and developmental angiogenesis. Although the Tie2 Cre deleter mice also express Cre in hematopoietic cells, 28 we did not observe any gross defects in blood cells, suggesting epsin deletion in hematopoietic cells did not contribute to defective embryonic angiogenesis and lethality. Second, the inducible iCDH5 Cre deleter mice allowed us to study a specific role of endothelial epsins in regulating VEGFR2 in adult mice. Importantly, postnatal epsin deletion does not affect quiescent angiogenesis. 26 Our findings support a model in which inhibiting activated VEGFR2 internalization and degradation through loss of epsins accumulates VEGFR2 on cell surface, prolongs VEGF signaling, and promotes angiogenesis. Reduction of VEGFR2 by genetic means suppressed the enhanced VEGF signaling and restored normal angiogenesis. Although receptor internalization is a recognized mechanism of signal modification, it is still unclear whether VEGFR2 internalization promotes or hinders VEGF signaling to modulate angiogenesis. Impaired internalization or intracellular trafficking of phosphorylated VEGFR2 reportedly inhibited certain intracellular signals, such as Ras homology gene family of GTPases, member A (RhoA) activation, but enhances others, such as Akt activation. 36, 38, 39 For example, loss of the endocytic adaptor protein, Dab2, impaired VEGFR2 internalization resulting in reduced downstream signaling to ERK and impaired neovascular angiogenesis. 38 Similarly, depletion of the class II PI3K, C2α, impaired VEGFR2 intracellular trafficking resulting in impaired RhoA activation and formation of endothelial focal adhesions. Given the implicated roles of class II PI3K and Dab2 in receptor endocytosis and trafficking to the endosomes, it is tempting to speculate that impaired internalization of phosphorylated VEGFR2 prevents VEGFR2 traveling to or affects the formation of signaling endosomes responsible for signal enhancement. In contrast, epsins interacted with ubiquitinated VEGFR2, presumably after prolonged activation, and, as suggested by our findings, targeted ubiquitinated VEGFR2 for lysosomal degradation, thus effectively diminishing VEGF signaling. 26 Loss of epsins prevented targeted VEGFR2 degradation, which may, in turn, have promoted VEGFR2 recycling and prolonged signaling, resulting in enhanced EC proliferation, migration, and network formation responsible for aberrant angiogenesis. However, we cannot discount that, through impaired internalization of phosphorylated VEGFR2, epsins may also be inhibiting RhoA activation resulting in impaired focal adhesion formation in vivo, thus contributing to our leaky vascular phenotype. Our findings, in combination with those from Dr Takuwa's group, strongly suggest that tight modulation of VEGF signaling through VEGFR2 internalization and differential downstream signal regulation is necessary to ensure proper angiogenesis. 41 Our previous findings support epsins as potential anticancer therapeutic targets that promoted aberrant tumor angiogenesis and retarded tumor growth. 26 We speculated that altering epsins may prove favorable in angiogenic-dependent conditions such as wound healing. Although we demonstrated that endothelial epsin deletion impaired, rather than promoted, wound healing under normal conditions, interestingly, in conditions in which angiogenesis is compromised, such as diabetic ulcers, we found that epsin deletion promoted wound healing in STZ-induced diabetic models, suggesting that modulating endothelial epsins may be beneficial. Cumulatively, these findings establish a role for epsins in developmental and pathological angiogenesis and further fortify that epsins modulate VEGF signaling by specifically downregulating VEGFR2 levels. and American Heart Association grant 12SDG876002 to Y. Dong; American Heart Association pre-doctoral fellowship RSRCH016952 to X. Liu; and American Heart Association postdoctoral fellowships 13POST16940008 to K.L. Tessneer and 13POST17270006 to S. Pasula.
